Takeshi Yamamotoya

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Shirong Qiang, Yusuke Nakatsu, Yasuyuki Seno et al. · Diabetology & Metabolic Syndrome · 2015 · 112 citations · Full text

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

Yusuke Nakatsu, Hiroki Kokubo, Bumdelger Batmunkh et al. · International Journal of Molecular Sciences · 2017 · 88 citations · Full text

Immunology, Native Apoe Ko, Hyperlipidemia +22

The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model

Yusuke Nakatsu, Yasuyuki Seno, Akifumi Kushiyama et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2015 · 83 citations

Metabolic Disorder, Rodent Model, Pathology +21

Protective Effect of Sex Hormone-Binding Globulin against Metabolic Syndrome:<i>In Vitro</i>Evidence Showing Anti-Inflammatory and Lipolytic Effects on Adipocytes and Macrophages

Hiroki Yamazaki, Akifumi Kushiyama, Hideyuki Sakoda et al. · Mediators of Inflammation · 2018 · 80 citations · Full text

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice

Masa-ki Inoue, Yasuka Matsunaga, Yusuke Nakatsu et al. · Diabetology & Metabolic Syndrome · 2019 · 60 citations · Full text